echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > EHA hot spot: A number of phase III studies of C5 complement inhibitor Crovalimab have entered the recruitment phase, and the research and development in China is synchronized with the global

    EHA hot spot: A number of phase III studies of C5 complement inhibitor Crovalimab have entered the recruitment phase, and the research and development in China is synchronized with the global

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Paroxysmal nocturnal hemoglobinuria (Paroxysmal nocturnal hemoglobinuria, PNH) is a rare acquired clonal disease of hematopoietic stem cells in which the PIG-A gene mutation on somatic cells xp22.
    1 leads to dysregulation of the complement system

    Different degrees of intravascular hemolysis, bone marrow hematopoietic dysfunction and thrombosis have brought a great disease burden to PNH patients and affected the survival of patients

    In foreign countries, complement C5 inhibitors have become the standard treatment for PNH; however, in China, such drugs are not yet available, and there is still a large unmet need for the treatment of PNH

    A new generation of C5 complement inhibitor, circulating antibody Crovalimab Crovalimab is a new generation of C5 inhibitor engineered through continuous monoclonal antibody recovery technology (Smart-Ig).
    It has a long half-life, can be injected subcutaneously, and is the same for patients with C5 polymorphisms.
    There is curative effect

    The Phase I/II COMPOSER trial showed superior efficacy and safety data, which enabled crovalimab to enter the phase III clinical trial phase smoothly

    Diagram of the mechanism of action of the Crovalimab circulating antibody: After crovalimab binds to complement C5, it undergoes endocytosis and dissociates under the acidic environment of endosomes, and then C5 is degraded in the lysosome; while crovalimab interacts with the neonatal Fc receptor ( FcRn) is combined to recycle to the outside of the cell for further recycling.
    At the 26th European Annual Conference on Blood (EHA) this year, crovalimab announced three important research designs, including two important phase III clinical trials (COMMODORE 1, COMMODORE) 2), and a study related to the burden of PNH disease (COMMODORE BoI)

    01Crovalimab's multiple key phase III clinical trials have entered the recruitment phase (PB1480).
    At present, there are 3 crovalimab phase III clinical trials that have entered the recruitment phase around the world.
    Among them, COMMODORE 1 and COMMODORE 2 are crovalimab versus eculizumab.
    Efficacy and safety studies in PNH patients who have previously received C5 complement inhibitors and have not received C5 complement inhibitor treatment

    In addition, multiple centers in mainland China are conducting COMMODORE 3 trials at the same time.
    This single-arm study is to verify the efficacy and safety of crovalimab in PNH patients ≥12 years of age who have not previously received C5 complement inhibitor therapy

    COMMODORE 1 study design plan: C5 complement inhibitor treated population COMMODORE 2 study design plan: naive population COMMODORE 3 (Chinese single-arm trial) study design plan: naïve population 02PNH disease burden study (PB1486) has not yet been tested in C5 complement inhibitors In accessible areas, the incidence of complications such as thrombosis and kidney injury in PNH patients is higher, the quality of life of the patients is poor, and the 5-year mortality rate is about 35%

    In areas where C5 complement inhibitors are accessible, treatment costs, reimbursement problems, differences in drug efficacy, and inconvenience in administration methods, still bring a heavier burden of disease to the medical system and PNH patients

    Therefore, robust data on the real-life burden and cost of PNH are needed to assess the impact of current treatments and establish a baseline for new treatments

    COMMODORE BoI is an international, prevalence-based, bottom-up disease burden study, including retrospective and prospective data collection

    Doctors will use electronic case record forms (eCRF) to provide information about sociodemographic, clinical and medical resource utilization

    At the same time, the patient report outcome (PRO) survey will provide further information on the impact of PNH on the economy and HRQOL

    The study will include a total of 94 doctors from France, Germany, the United Kingdom and China.
    They will report 350 patient eCRFs and are expected to collect 140 patient surveys

    Related research results will be announced in early 2022

    Conclusion The clinical trials of Crovalimab are being carried out simultaneously at home and abroad.
    It is expected that the clinical research data will be released as soon as possible, and domestic PNH patients can use the standard treatment plan of C5 complement inhibitor as soon as possible

    In addition, there is still a lack of disease burden research in the field of PNH in China.
    The development of such research will help to formulate relevant medical and health policies and truly serve patients.
    It is hoped that domestic counterparts will work together to explore more effective diagnosis and treatment paths in the field of PNH

    References: 1.
    Du, et al.
    2016, 38, e84–e85.
    Fukuzawa T et al, Sci Rep, 2017, Apr 24;7(1):1080.
    Nishimura J et al.
    N Engl J Med.
    Röth A et al, Blood, 20205.
    CTR20201931 and CTR20210827 research information: http:// COMMODORE3 (NCT04654468): https:// COMMODORE 1(NCT04432584): https:// term=crovalimab&draw=2&rank=38.
    COMMODORE 2(NCT04434092): https:// stamp "read the original text" and we will make progress together
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.